Figure 8.
Effect of GP-17 on ERα in Ox-LDL-treated HUVECs. (A) Localization of ERα immunoreactivity was identified in the cytoplasm by immunofluorescence assays; (B) Localization of ERα immunoreactivity was identified in the plasma membrane by immunofluorescence assay; (C,D) The expressions of both ERα and ERβ were analyzed by western blots of Ox-LDL-induced HUVECs. The values are expressed as the mean ± S.E.M. from three independent experiments. ## p < 0.01 vs. Control; * p < 0.05 vs. Ox-LDL; & p < 0.05 vs. GP-17 + Ox-LD. DAPI, 4,6-diamidino-2-phenylindole.